Savara (SVRA) Shares Outstanding (Diluted Average) (2021 - 2026)
Savara (SVRA) reported Shares Outstanding (Diluted Average) of $253.3 million for Q1 2026, up 17.18% year-over-year from $216.1 million in Q1 2025, and up 13.89% quarter-over-quarter from $222.4 million in Q4 2025.
Savara (SVRA) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Savara (SVRA) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $253.3 million in Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $253.3 million, up 17.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $253.3 million (up 17.18% YoY), and the FY2025 annual result was $222.4 million, up 12.21% from the prior year.
- Shares Outstanding (Diluted Average) advanced to $253.3 million in Q1 2026 per SVRA's latest filing, from $222.4 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $253.3 million in Q1 2026 and troughed at $152.8 million in Q1 2022.
- A 5-year average of $184.5 million and a median of $182.6 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) climbed 0.01% in 2023, then climbed 19.97% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $152.8 million in 2022, then climbed by 8.14% to $165.2 million in 2023, then rose by 19.97% to $198.2 million in 2024, then rose by 12.21% to $222.4 million in 2025, then climbed by 13.89% to $253.3 million in 2026.
- Business Quant data shows SVRA's Shares Outstanding (Diluted Average) at $253.3 million in Q1 2026, $222.4 million in Q4 2025, and $216.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 253.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253.28 Mn |
| Dec 31, 2025 | 222.39 Mn |
| Sep 30, 2025 | 216.46 Mn |
| Jun 30, 2025 | 216.29 Mn |
| Mar 31, 2025 | 216.15 Mn |
| Dec 31, 2024 | 198.19 Mn |
| Sep 30, 2024 | 192.40 Mn |
| Jun 30, 2024 | 182.57 Mn |
| Mar 31, 2024 | 182.55 Mn |
| Dec 31, 2023 | 165.20 Mn |
| Sep 30, 2023 | 174.70 Mn |
| Jun 30, 2023 | 152.80 Mn |
| Mar 31, 2023 | 152.78 Mn |
| Dec 31, 2022 | 152.77 Mn |
| Sep 30, 2022 | 152.77 Mn |
| Jun 30, 2022 | 152.77 Mn |
| Mar 31, 2022 | 152.77 Mn |
| Dec 31, 2021 | 133.92 Mn |
| Sep 30, 2021 | 127.62 Mn |
| Jun 30, 2021 | 152.46 Mn |